Clinical Trial Update: A Study to Compare Administration Schedules of G-CSF (Filgrastim) for Primary Prophylaxis of Febrile Neutropenia [Phase 4]

View source ↗

Summary

Phase 4 trial updating administration schedules of G-CSF (Filgrastim) for primary prophylaxis of febrile neutropenia in early stage breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Filgrastim (filgrastim)

Snippet

Sponsor: Ottawa Hospital Research Institute | Conditions: Early Stage Breast Cancer | Phase 4 | Status: COMPLETED